Survey of the management of borderline ovarian tumors in the United Kingdom

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

358

HTML

4473

Tables (1-3)

193

Sum=5024

Aug 10, 2012 (publication date) through Jul 19, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Obstetrics and Gynecology

ISSN

2218-6220

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Obstet Gynecol. Aug 10, 2012; 1(2): 3-13
Published online Aug 10, 2012. doi: 10.5317/wjog.v1.i2.3

Table 3 Use of chemotherapy in treatment of borderline ovarian tumors in United Kingdom centres

Use of chemotherapy	Percentage of centres (%)
In the adjuvant setting
No chemotherapy used	46
Chemotherapy used only if there is invasive disease	23
Chemotherapy used	31
First line treatment of advanced (stage III or recurrent) disease
No chemotherapy used	8.3
Chemotherapy used	91.6

Chemotherapy used is carboplatin ± paclitaxel.

Citation: Winser A, Ledermann JA, Osborne R, Gabra H, El-Bahrawy MA. Survey of the management of borderline ovarian tumors in the United Kingdom. World J Obstet Gynecol 2012; 1(2): 3-13
URL: https://www.wjgnet.com/2218-6220/full/v1/i2/3.htm
DOI: https://dx.doi.org/10.5317/wjog.v1.i2.3